Babraham Research Campus
29 articles with Metrion Biosciences
9/11/2020Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, announced it has significantly enhanced its global business development capabilities, with additional resources now committed to support key regions in the USA, Europe and Japan.
Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of New Medicines
Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, announced it has contributed to two new peer-reviewed papers under the U.S. Food and Drug Administration’s CiPA initiative.
12/5/2019Companies from across the globe provide updates on their business and pipelines.
Metrion Biosciences and LifeArc Extend Ion Channel Drug Discovery Collaboration to Accelerate Neuroscience-focused Research
Initial twelve month collaboration successfully identifies hit compounds and progresses into hit-to-lead optimisation phase
4/12/2019Biopharma companies tap new hires to assume roles in leadership positions, with additions at Metrion, JDRF, Ribometrix, and more.
Metrion Biosciences, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect.
Across the globe, pharma and biotech companies report deals and pipeline updates, with news from Boehringer Ingelheim, Metrion, Elvie, and more.
Funding to support expansion of ion channel screening capabilities and continued research into potential drugs for auto-immune diseases
It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup...
Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK medical research charity, today announced they have entered into a collaboration agreement for an ion channel drug discovery project in the field of neuroscience
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Dr Edward Stevens appointed as Head of Drug Discovery, and Dr Andrew Lightfoot as Head of Medicinal Chemistry and Discovery Funding
Metrion Biosciences awarded £637k funding under Innovate UK Biomedical Catalyst Primer Award for ion channel drug discovery
Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has been awarded £637k funding under the Innovate UK Biomedical Catalyst Primer Award scheme.
The members of the SAB have been selected for their extensive and diverse experience in ion channel screening, cardiac safety testing, neuroscience research and native tissue and human stem cell translational assays, all of which are fields of interest to Metrion.
Metrion Biosciences, the specialist ion channel contract research and drug discovery company, announced today it has been awarded £200k funding under the Innovate UK Biomedical Catalyst Feasibility Award scheme.
Metrion Biosciences Acquires Rights to Small Molecule Potassium Channel Inhibitors From Japan Tobacco
The portfolio includes compounds covered by five separate patent applications, together with several new unpatented chemical series.
Metrion Biosciences Opens £600k Investment Round Through SyndicateRoom to Support Growth of Services Business
Metrion will use the funds to expand its rapidly growing fee-for-service business.
LifeArc And Metrion Biosciences Extend Partnership Agreement To Support LifeArc’s Neuroscience Small Molecule Drug Discovery Programme